Russian cystic fibrosis patients have raised concerns with prosecutors about safety monitoring gaps and potential adverse reactions to 'Trileksa,' an Argentine generic that replaced the original 'Trikafta' in state procurement in late 2024. Parents report that hospitals are blocking adverse event reports and that regulators are not registering side effects, while clinical trials conducted on the Russian replacement drug were limited to bioequivalence studies on healthy volunteers rather than efficacy and safety assessments in actual CF patients.